HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

GH therapy in Noonan syndrome: Review of final height data.

AbstractBACKGROUND AND AIMS:
Several studies, despite using small cohorts, have shown a short-term improvement in the height velocity of short children with Noonan syndrome (NS) when treated with recombinant growth hormone (GH). However, the question is whether or not this improvement is sustained until adult height is reached. This paper reviews the few studies reporting final height data of GH treatment in individuals with NS.
METHODS:
Review of published papers from 4 main and several small studies with final height data after GH treatment in NS.
RESULTS:
The range of height gain to adult age varies between 0.6 and 2.0 SDS, depending on genotype, age at start of treatment, duration of treatment and which growth charts are used. The younger the age at which treatment is started, the better the result. There seems to be a correlation between growth response and genotype, with a diminished growth response when the PTPN11 mutation is present.
CONCLUSION:
Data on the benefits of GH treatment during childhood and adolescence upon the final height are encouraging in individuals with NS. There is a substantial height gain during prepubertal years, which continues during the pubertal period, reaching a final height within the normal population in the majority of previously short individuals with NS.
AuthorsJovanna Dahlgren
JournalHormone research (Horm Res) Vol. 72 Suppl 2 Pg. 46-8 (Dec 2009) ISSN: 1423-0046 [Electronic] Switzerland
PMID20029237 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright2009 S. Karger AG, Basel.
Chemical References
  • Human Growth Hormone
  • PTPN11 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 11
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Body Height
  • Child
  • Female
  • Genotype
  • Growth
  • Human Growth Hormone (administration & dosage, therapeutic use)
  • Humans
  • Male
  • Mutation
  • Noonan Syndrome (drug therapy, genetics, physiopathology)
  • Protein Tyrosine Phosphatase, Non-Receptor Type 11 (genetics)
  • Puberty
  • Sex Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: